Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence

Clinical Cancer Research

Volumn 14, Issue 13, 2008, Pages 4111-4118

  Caruso, Daniel J ^a   Carmack, Adrienne J K ^a   Lokeshwar, Vinata B ^a,b   Duncan, Robert C ^a   Soloway, Mark S ^a   Lokeshwar, Bal L ^a,b,c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 8; OSTEOPONTIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SEMINAL VESICLE; SENSITIVITY AND SPECIFICITY; BIOSYNTHESIS; DISEASE COURSE; GENE EXPRESSION REGULATION; METABOLISM; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROSTATE TUMOR; RECURRENT DISEASE; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-8; MALE; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOPONTIN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 48249112605     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0738     Document Type: Article

References (26)

1. Amling CL. Biochemical recurrence after localized treatment. Urol Clin North Am 2006;33:147-59.
2. Routh JC, Leibovich BC. Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo Clin Proc 2005;80:899-907.
3. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000;11:279-303.
4. Ravallese EM. Osteopontin: a bridge between bone and the immune system. J Clin Invest 2003;112:147-9.
5. Erratum in: J Clin Invest 2003;112:627.
6. Rangaswami M, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006;16:79-87
7. Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002;62:3417-27.
8. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001;7:4060-6.
9. Khodavirdi AC, Song Z, Yang S, et al. Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 2006;66: 883-8.
10. Forootan SS, Foster CS, Aachi VR, et al. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer 2006;118:2255-61.
11. Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci 2008;103:4-13.
12. Kim SJ, Uehara H, Karashima T, McCarty M, Shih N, Fidler IJ. Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia 2001;3:33-42.
13. Araki S, Omori Y, Lyn D, et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 2007;67: 6854-62.
14. Uehara H. Troncoso P Johnston D, et al. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 2005;64:40-9.
15. Lehrer S, Diamond EJ, Mamkine B, Stone NN, Stock RG. Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. Technol Cancer Res Treat 2004;3:411.
16. Michaud DS, Daugherty SE, Bemdt SI, et al. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 2006;66:4525-30.
17. Yang HP, Woodson K. Taylor PR, et al. Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer among Finnish men in a large cancer prevention trial. Eur J Cancer Prev 2006;15:249-53.
18. Attur MG, Dave MN, Clancy RM, Patel IR, Abramson SB, Amin AR. Functional genomic analysis in arthritisaffected cartilage: yin-yang regulation of inflammatory mediators by α 5 β 1 and α V β 3 integrins. J Immunol 2000;164:2684-91.
19. Cohen BL, Gomez P, Omori Y, et al. Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int J Cancer 2006; 119:1082-7.
20. Lokeshwar VB, Habuchi T, Grossman HB, et al Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005;66:35-63.
21. Canto El, Shariat SF, Slawin KM. Biochemical staging of prostate cancer. Urol Clin North Am 2003;30: 263-77.
22. Braeckman J, Michielsen D. Prognostic factors in prostate cancer Recent Results Cancer Res 2007: 175:25-32
23. Schalken JA, Bergh A, Bono A, et al. Molecular prostate cancer pathology: current issues and achievements. Scand J Urol Nephrol Suppl 2005; 216:82-93.
24. FlaigTW, Nordeen SK, Lucia MS, Harrison GS, Glode LM. Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes. J Urol 2007;177:1229-37
25. Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177: 540-5.
26. Rowley DR. Stromal response mean to prostate cancer progression? Cancer Metastasis Rev 1998;17: 411-9.